Since then, Crk knockdown has been demonstrated to result in decreases in cancer cell migration and invasion in ovarian cancer [28,29], synovial cell carcinoma [52], glioblastoma [41], oral squamous cell carcinoma [53], prostate cancer [54,55], breast cancer [26], gastric cancer [59], bladder cancer [45], and pancreatic ductal adenocarcinoma [60] cells. This evidence concerns the gene CRK and prostate cancer.